Methodist Research Institute
- CLINICAL RESEARCH GROUP
- MEDICAL RESEARCH LABORATORY
- BIOSTATISTICS & DATA SERVICES
- BIOMEDICAL COMMUNICATION
- INDIANA CENTER FOR BIOMEDICAL INNOVATION
- Institutional Biosafety Committee
- Medical Library
The Neuroscience Research Laboratory has closed.
John Bright, PhD
- Rafi MM, Kanakasabai S, Gokarn SV, Drudger EG, Bright JJ. Dietary lutein modulates growth and survival genes in prostate cancer cells. J Med Food. Feb 2015;18(2):173-181. Link
- Rafi M, Kanakasabai S, Reyes MD, Bright JJ. Lycopene modulates growth and survival associated genes in prostate cancer. J Nutr Biochem. Oct 2013;24(10):1724-1734. Link
- Kanakasabai S, Pestereva E, Chearwae W, Gupta SK, Ansari S, Bright JJ. PPARgamma agonists promote oligodendrocyte differentiation of neural stem cells by modulating stemness and differentiation genes. PloS one. 2012;7(11): e50500. Link
- Kanakasabai S, Casalini E, Walline CC, Mo C, Chearwae W, Bright JJ. Differential regulation of CD4(+) T helper cell responses by curcumin in experimental autoimmune encephalomyelitis. J Nutr Biochem. Mar 6 2012. Link
- Walline CC, Kanakasabai S, Bright JJ. IL-7Ralpha confers susceptibility to experimental autoimmune encephalomyelitis. Genes Immun. Jan 2011;12(1):1-14. Link
- Kanakasabai S, Walline CC, Chakraborty S, Bright JJ. PPARdelta deficient mice develop elevated Th1/Th17 responses and prolonged experimental autoimmune encephalomyelitis. Brain Res. Feb 28 2011;1376:101-112. Link
- Chakraborty S, Kanakasabai S, Bright JJ. Constitutive androstane receptor agonist CITCO inhibits growth and expansion of brain tumour stem cells. Br J Cancer. Feb 1 2011;104(3):448-459. Link
- Mo C, Chearwae W, Bright JJ. PPARgamma regulates LIF-induced growth and self-renewal of mouse ES cells through Tyk2-Stat3 pathway. Cell Signal. Mar 2010;22(3):495-500. Link
- Kanakasabai S, Chearwae W, Walline CC, Iams W, Adams SM, Bright JJ. Peroxisome proliferator-activated receptor delta agonists inhibit T helper type 1 (Th1) and Th17 responses in experimental allergic encephalomyelitis. Immunology. Aug 2010;130(4):572-588. Link
Dr. Bright earned his BSc, MSc, and MPhil degrees in Zoology while at Madurai Kamaraj University in Tamil Nadu, India. He received his PhD in Biochemistry from the University of Kerala in Trivandrum, India in 1993 and then served as a post-doctoral fellow for two years at the Centre for Cellular and Molecular Biology in Hyderabad, India.
Dr. Bright immigrated to America in 1994 and spent two years as a post-doctoral fellow in the Neurology Department at Vanderbilt. From 1996-98, he worked as a Research Associate in the Neurology department, supported by an advanced postdoctoral fellowship from the National Multiple Sclerosis Society. From 1998-99 Dr. Bright served on the Vanderbilt faculty as an Instructor of Neurology, becoming a tenure-track Assistant Professor of Neurology in 1999. He also served as Assistant Professor of Pharmacology and as a member of the Vanderbilt Ingram Cancer Center. After six years on the faculty at Vanderbilt University Medical Center in Nashville, Dr. Bright moved to Indianapolis in 2005 as the Senior Investigator and founding director of the Neuroscience Research Laboratory at the Methodist Research Institute.
Dr. Bright's research interests are relevant to cancer, stem cells, inflammation, and autoimmune diseases of the brain. His research has been funded by the NIH and NMSS, and he participates in grant reviews for the NIH and other foundations. Dr. Bright has received several honors and awards for his work, which has been published in peer-reviewed journals. He is a member of the American Association of Immunologists, the American Association for Cancer Research, the International Society of Neuroimmunology, and the International Society for Stem Cell Research.